WCN24-1144 ECULIZUMAB IN TYPICAL SHIGA TOXINASSOCIATED HUS: A SINGLE CENTER EXPERIENCE

WCN24-1144 ECULIZUMAB IN TYPICAL SHIGA TOXINASSOCIATED HUS: A SINGLE CENTER EXPERIENCE

Saved in:

Bibliographic Details
Main Authors:	Vivarelli Marina, Federica zotta, Debora Vezzoli, Antonio Gargiulo, Alessandra Gianviti
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924007915
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-1027 THE ALTERNATIVE COMPLEMENT PATHWAY IN SHIGA TOXIN-PRODUCING ESCHERICHIA COLI– ASSOCIATED HEMOLYTIC UREMIC SYNDROME (STEC-HUS)
by: Patricia G. Vallés, et al.
Published: (2024-04-01)

WCN24-1143 GENETIC ANALYSIS IN DIARRHEA-ASSOCIATED STEC NEGATIVE HEMOLYTIC UREMIC SYNDROME
by: Marina Vivarelli, et al.
Published: (2024-04-01)

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
by: Chia Wei Teoh, et al.
Published: (2018-01-01)

Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
by: Franz Schaefer, et al.
Published: (2024-09-01)

WCN24-2091 A Case of Smoldering Atypical HUS Superimposed on Familial FSGS
by: Elias Bassil, et al.
Published: (2024-04-01)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
by: Louis Manière, et al.
Published: (2019-01-01)

WCN24-1340 Kidney function trajectory in 152 STEC-HUS patients followed for more than 15 years
by: Lucas Lucarelli, et al.
Published: (2024-04-01)

The frequency of detection of markers of Сytomegalovirus infection in children with recurrent respiratory diseases in patients with Shiga-toxin-associated hemolytic-uremic syndrome (STEC-HUS)
by: I. B. Repina, et al.
Published: (2021-04-01)

WCN25-1144 A CASE REPORT OF A 79 YEAR-OLD FEMALE WITH ALUMINUM TOXICITY PRESENTING AS ALTERED MENTAL STATUS , ELDORET, KENYA
by: Ann Mutugi, et al.
Published: (2025-02-01)

Synthesis, Characterization, and Measurement of New 1144‐Type Iron‐Based Superconductors: A Systematic Review
by: Gedefaw Mebratie, et al.
Published: (2025-04-01)

WCN24-640 ECULIZUMAB SPARING PROTOCOLS IN RENAL TRANSPLANTATION OF CASES OF ATYPICAL HEMOLYTIC UREMIC SYNDROME: A ONE YEAR FOLLOW UP STUDY
by: Kartik Ganesh, et al.
Published: (2024-04-01)

“Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Federica Maritati, et al.
Published: (2024-04-01)

Eculizumab in Posttransplant TMA: Unproven Benefit
by: Romy N. Bouwmeester, et al.
Published: (2024-06-01)

Scene Understanding by Fused Hu’s Invariant Moments and Deep Learning Features
by: Michael Nachipyangu, et al.
Published: (2025-01-01)

Platelet thrombus formation in eHUS is prevented by anti-MBL2.
by: R I Kushak, et al.
Published: (2019-01-01)

Innovaciones léxicas documentadas en el tének colonial (HUS; maya)
by: Lucero Melendez Guadarrama
Published: (2023-11-01)

Clinical case of recurrent aHUS after allogeneic cadaveric kidney transplantation
by: S. V. Popov, et al.
Published: (2024-01-01)

Commemorating Jubilee of Jan Hus in Russian Empire: Preconditions, History, Cultural Context.
by: K. B. Egorova
Published: (2024-04-01)

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients
by: Valeria Guaschino, et al.
Published: (2025-06-01)

WCN25-809 NOT YOUR TYPICAL MGUS
by: Sreedhar Mandayam, et al.
Published: (2025-02-01)

Transplant-associated Thrombotic Microangiopathy: An Enigma Treated with Eculizumab
by: S. Ravitej, et al.
Published: (2024-10-01)

Response to Letter to the Editor From Bouwmeester RN et al.: “Eculizumab in Postransplant TMA: Unproven Benefit.”
by: Federica Maritati, et al.
Published: (2024-06-01)

WCN25-1329 Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome
by: Andrea Angeletti, et al.
Published: (2025-02-01)

Demographics and baseline disease characteristics of UK patients within the global aHUS registry
by: Rodney D. Gilbert, et al.
Published: (2025-08-01)

Defining the role of Hmu and Hus systems in Porphyromonas gingivalis heme and iron homeostasis and virulence
by: Michał Śmiga, et al.
Published: (2024-12-01)

Response to “A Caution Against the Use of C5B-9 Endothelial Assay to Support Eculizumab Therapy”
by: Federica Maritati, et al.
Published: (2024-05-01)

Response to Letter to the Editor From Ville S. et al. About: “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Federica Maritati, et al.
Published: (2024-06-01)

Characterization of Seven Shiga Toxin Phages Induced from Human-Derived Shiga Toxin-Producing <i>Escherichia coli</i>
by: Xinxia Sui, et al.
Published: (2025-03-01)

Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)
by: E. Yu. Prudnikova, et al.
Published: (2017-03-01)

Meningococcemia in a vaccinated child receiving eculizumab and review of the literature
by: Diana Üçkardeş, et al.
Published: (2023-02-01)

A Case of Neisseria sicca Bacteremia Due to Eculizumab Therapy
by: Kelly A. Russo, et al.
Published: (2023-06-01)

Predicting Urosepsis in Ureteral Calculi: External Validation of Hu’s Nomogram and Identification of Novel Risk Factors
by: Yuka Sugizaki, et al.
Published: (2025-04-01)

WCN24-1146 SAFETY AND EFFICACY OF IPTACOPAN IN ADOLESCENT PATIENTS WITH IDIOPATHIC (PRIMARY) IMMUNE-COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
by: Nicholas Webb, et al.
Published: (2024-04-01)

Letter to the editor about: “Eculizumab First” in the Management of Posttransplant Thrombotic Microangiopathy
by: Simon Ville, et al.
Published: (2024-06-01)

Enteroaggregative E. coli O104 from an outbreak of HUS in Germany 2011, could it happen again?
by: Marie Anne Chattaway, et al.
Published: (2011-07-01)

Escherichia coli (STEC) serotype O104 outbreak causing haemolytic syndrome (HUS) in Germany and France
by: Salvatore Rubino, et al.
Published: (2011-07-01)

Effective Management of Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma Using Eculizumab
by: Jennifer Kim, et al.
Published: (2025-06-01)

Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
by: Olesya U. Klimova, et al.
Published: (2025-01-01)

Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections
by: Yufei Deng, et al.
Published: (2025-07-01)

Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study
by: Lei Jin, et al.
Published: (2024-12-01)